GENE ONLINE|News &
Opinion
Blog

2021-03-23| In-DepthM&ASpecial

Overview of the Gene Therapy Revolution: Hopeful Beginnings, Tribulations, and Resurgence

by Rajaneesh K. Gopinath
Share To
Gene therapy is a hot commodity in the biopharma business, attracting profitable investments and expensive M&A transactions in recent years.

Moreover, the frequent reports of research breakthroughs and clinical trial gains are an indication of the steady progress of the field. In 2019, the gene therapy market was valued at $3.61 billion. It is predicted to grow further at a CAGR of 33.6% and reach $35.67 billion by 2027, according to a forecast released by Fortune Business Insights™.

GO Prime with only $1.49 now

LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
EVENT
Scroll to Top